Substance P infused into the striatum relieved inflammatory pain at 3 days but not 7 days, because persistent inflammation downregulated NK1 receptors in the brain.
Effective at day 3, not day 7Persistent inflammation downregulated striatal NK1 receptors, eliminating substance P antinociceptive effect
What the researchers found
Striatal substance P via NK1 receptors provides antinociception in acute (3-day) but not subacute (7-day) inflammatory pain, due to inflammation-induced NK1 receptor downregulation.
Why it matters
Understanding when neuropeptide pain pathways work — and when they stop working — is critical for developing effective pain treatments and understanding why chronic pain becomes treatment-resistant.
The numbers in context
Day 3: SP reduced allodynia (NK1R-dependent); Day 7: SP ineffective; NK1R protein decreased at day 7; paw edema unaffected
How the study worked
Animal study using reverse microdialysis to continuously infuse substance P into rat dorsal striatum, measuring mechanical allodynia and paw edema at 3 and 7 days after CFA-induced inflammation, with NK1 receptor protein quantification.
Who was studied
Rats with CFA-induced hind paw inflammation; continuous striatal substance P infusion
What this study cannot tell us
Rat model with direct brain infusion — not a practical delivery route; single inflammatory model (CFA); mechanism of NK1 downregulation not fully characterized.
How to read the evidence
Well-controlled animal study with pharmacological validation and receptor protein measurements, but limited to one pain model and invasive delivery route.
When this study was published
Published in 2020; complements the parallel study on substance P in neuropathic pain (same research group).
The bigger picture
This study reveals that persistent inflammation can downregulate the brain's own pain-relief neuropeptide receptors, potentially explaining why chronic pain becomes harder to treat over time.
Questions still open
- Can NK1 receptor downregulation be prevented to maintain substance P pain relief during chronic inflammation?
- Does this receptor downregulation occur in human chronic pain conditions?
- Could early substance P intervention prevent the transition from acute to chronic pain?
Common questions
Can substance P reduce pain?
Why does pain become harder to treat over time?
Read the original research
Continuous infusion of substance P inhibits acute, but not subacute, inflammatory pain induced by complete Freund's adjuvant.
Biochemical and biophysical research communications, 533(4), 971-975
Citation
Nakamura, Yoki; Fukushige, Ryo; Watanabe, Kohei; Kishida, Yuki; Hisaoka-Nakashima, Kazue; Nakata, Yoshihiro; Morioka, Norimitsu. (2020). Continuous infusion of substance P inhibits acute, but not subacute, inflammatory pain induced by complete Freund's adjuvant.. Biochemical and biophysical research communications, 533(4), 971-975. https://doi.org/10.1016/j.bbrc.2020.09.113